Pharma Exclusives Pressreleases
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate
Tuesday, June 03, 2025BioNTech SEand Bristol Myers Squibb today announced that the companies have entered into an agreement for the global codevelopment and cocommercialization of BioNTechs investigational bispecific antibody BNT
Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
Tuesday, June 03, 2025Roche announced today positive results from the Phase III IMforte study of Tecentriq atezolizumab in combination with lurbinectedin Zepzelca as a firstline maintenance treatment for people with extensivestage
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
Saturday, May 31, 2025Teva Pharmaceuticals a US affiliate of Teva Pharmaceutical Industries Ltd NYSE and TASE TEVA today announced results from a study of treatment patterns among patients with tardive dyskinesia TD residing
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis
Friday, May 30, 2025Roche announced today new week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis RMS maintained no disability progression and low levels of disease activity for up to two years
Moderna Announces Update on Investigational Pandemic Influenza Program
Thursday, May 29, 2025Moderna Inctoday announced positive interim data from a Phase clinical study NCT evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine mRNA in approximately healthy adults aged years and older
TQ Therapeutics GmbH Announces Acquisition of Juno Therapeutics GmbH
Wednesday, May 28, 2025TQ Therapeutics GmbH TQx a biotechnology company dedicated to advancing the field of cellular therapies through innovative technologies today announced the acquisition of Juno Therapeutics GmbH Juno GmbH
DEBRA Research and Dermaliq Enter into a Strategic Collaboration to Advance Cutaneous Drug Delivery for Epidermolysis Bullosa
Wednesday, May 28, 2025DEBRA Research GmbH a global nonprofit organization dedicated to advancing research and drug development for those affected by Epidermolysis Bullosa EB and Dermaliq Therapeutics Inc a clinicalstage
Hansa Biopharma plans restructuring to optimize resource allocation and improve operational efficiency
Tuesday, May 27, 2025Hansa Biopharma AB Hansatoday announced that it plans to restructure the organization to optimize resource allocation and improve operational efficiency The planned restructuring would result in an approximately reduction
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
Tuesday, May 27, 2025Teva Pharmaceutical Industries Ltd and Biolojic Design Ltd Biolojic a biotechnology company using computational biology and artificial intelligence to design next generation multifunctional antibodies known as multibodies
New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients
Friday, May 23, 2025Roche announced today twoyear followup data from the phase III STARGLO study After a median followup of months data showed a improvement in overall survival OS for patients treated with Columvi glofitamab in combination with gemcitabine and oxalipl...
